Stifel Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS) following in-line Q4

March 26, 2026 12:49 PM

Stifel analyst Paul Matteis reiterated a Buy rating and $10.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found